Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 7Rectal Neoplasms 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 13Doxorubicin 9Trastuzumab 8Taxes 7Paclitaxel 7Docetaxel 5Carboplatin 5Albumin-Bound Paclitaxel 5Radiotherapy 4Epirubicin 4pertuzumab 3pembrolizumab 3Melphalan 3130-nm albumin-bound paclitaxel 3eribulin 2Thiotepa 2Tamoxifen 2Peripheral Blood Stem Cell Transplantation 2Lapatinib 2Fluorouracil 2Filgrastim 2Bevacizumab 22C4 antibody 2trastuzumab biosimilar HLX02 1talimogene laherparepvec 1sargramostim 1ruxolitinib 1romidepsin 1pegfilgrastim 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Inflammatory Breast Neoplasms × 2C4 antibody × Clear all
NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
34 enrolled 15 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01730833 2025-06-03

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
63 enrolled 11 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡